Eidos Therapeutics to Present at the 2019 BMO Prescriptions for Success Healthcare Conference
18 June 2019 - 10:00PM
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that
management will participate in a fireside chat at the 2019 BMO
Prescriptions for Success Healthcare Conference on Tuesday, June
25th at 2:40 p.m. EDT in New York, NY.
A live audio webcast of the presentation can be accessed through
the Events & Presentations section of the company's website at
ir.eidostx.com. Archived replays of the webcast will be available
on the company's website for 90 days following the live
presentation.
About AG10
AG10 is an investigational, orally-administered small molecule
designed to potently stabilize tetrameric transthyretin, or TTR,
thereby halting at its outset the series of molecular events that
give rise to amyloidosis, or ATTR. In a Phase 2 clinical trial in
subjects with symptomatic ATTR-CM, AG10 was generally well
tolerated, demonstrated >90% average TTR stabilization at day
28, and increased serum TTR concentrations, a prognostic indicator
of survival in a retrospective study of ATTR-CM patients, in a
dose-dependent manner. AG10 is currently being studied in patients
with ATTR-CM in an open-label extension of a Phase 2 clinical trial
and in a Phase 3 clinical trial (ATTRibute-CM). ATTRibute-CM is a
pivotal global Phase 3 trial with two potentially registrational
endpoints. In Part A, benefit in change from baseline in 6-minute
walk distance (6MWD) will be evaluated at 12 months. In Part B,
reduction in all-cause mortality and frequency of
cardiovascular-related hospitalizations will be evaluated at 30
months.
AG10 was designed to mimic a naturally-occurring variant of the
TTR gene (T119M) that is considered a rescue mutation because
co-inheritance has been shown to prevent ATTR in individuals also
inheriting a pathogenic, or disease-causing, mutation in the TTR
gene. To our knowledge, AG10 is the only TTR stabilizer in
development that has been observed to mimic the stabilizing
structure of this rescue mutation.
About transthyretin amyloidosis (ATTR)
ATTR represents a significant unmet medical need with a large
patient population and an inadequate current standard of care. ATTR
is caused by the destabilization of TTR due to inherited mutations
or aging and is commonly divided into three distinct categories:
wild-type ATTR cardiomyopathy (ATTRwt-CM), mutant ATTR
cardiomyopathy (ATTRm-CM), and ATTR polyneuropathy (ATTR-PN). The
worldwide prevalence of each disease is approximately 400,000
patients, 40,000 patients and 10,000 patients, respectively.
All three forms of ATTR are progressive and fatal. For patients
with ATTRwt-CM and ATTRm-CM, symptoms usually manifest later in
life (age 50+), with median survival of three to five years from
diagnosis. ATTR-PN either presents in a patient's early 30s or
later (age 50+), and results in a median life expectancy of five to
ten years from diagnosis. Progression of all forms of ATTR causes
significant morbidity, impacts productivity and quality of life,
and creates a significant economic burden due to the costs
associated with progressively greater patient needs for supportive
care.
About Eidos Therapeutics
Eidos Therapeutics is a clinical stage biopharmaceutical company
focused on addressing the large and growing unmet need in diseases
caused by transthyretin (TTR) amyloidosis (ATTR). Eidos is
developing AG10, a potentially disease-modifying therapy for the
treatment of ATTR. For more information, please visit
www.eidostx.com.
Media Contact:
Carolyn Hawley, Canale Communications, (619) 849-5382,
carolyn@canalecomm.com
For Investors:
Alex Gray, Burns McClellan, (212) 213-0006,
agray@burnsmc.com
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Apr 2024 to May 2024
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From May 2023 to May 2024